Page 205 - Aet News Today

In an interview with MedCity News after his presentation at the J.P. Morgan Healthcare Conference, Wright Lassiter III said while some providers will be considered commodities, his vision for CommonSpirit Health is not to be "at the bottom of the totem pole."

NourishedRx is a food-as-medicine company that offers dietary assistance for health plans’ members through methods like medically-tailored meals, grocery support and diet education. Through the new platform, NourishedRx is able to communicate with its food partners, health plan customers and members.

Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $1.5 billion in milestone payments.

Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.

BioNTech says its InstaDeep acquisition will help it expand its use of artificial intelligence in drug discovery and development. The startup specializes in a type of machine learning called reinforcement learning.

Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.

Healthcare startup Novellia's platform seeks to digitally bring in all chapters of a patient's health journey to allow clinicians and researchers to finally see the full story.

Generally, behavioral health and substance use disorder are behind other specialties in collecting health equity data to lower outcome disparities. Data standardization, reporting requirements, and interoperability are critical to quickly addressing gaps.

Transcarent wants to transform the digital pharmacy benefit experience, enabling self-insured employers and their staff to make more informed choices.

AstraZeneca has committed $1.3 billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.